Eli Lilly Reports Positive Results for Oral Weight-Management Drug Trial
By Jiahui Huang
Eli Lilly & Co. reported positive topline results from a trial of its oral weight-management drug orforglipron.
In the Phase 3 trial, patients who had initially lost weight on Wegovy or Zepbound and were then switched to orforglipron. These patients maintained their weight better over a year than those given a placebo, the company said in a statement Thursday.
The results showed that "orforglipron, a once-daily oral GLP-1, helped people maintain the weight they worked hard to lose," said Kenneth Custer, the company's executive vice-president.
In the trial, participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average, the statement added.
Orforglipron belongs to the same family of GLP-1-based weight-loss drugs as Lilly's rival Novo Nordisk's Wegovy and Lilly's Zepbound, but can be administered orally rather than injected.
Lilly also has submitted a new drug application to the U.S. Food and Drug Administration for orforglipron for the treatment of overweight or obese adults.
Write to Jiahui Huang at jiahui.huang@wsj.com
(END) Dow Jones Newswires
December 18, 2025 06:59 ET (11:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States